Clinical Trial Update: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

The document reports ongoing Phase 1/2 clinical trials evaluating ponatinib in pediatric patients with recurrent or refractory leukemias, lymphomas, or solid tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Lymphoma
• Solid Tumor

Drugs mentioned

• Ponatinib (ponatinib)

Snippet

Sponsor: Incyte Biosciences International Sàrl | Conditions: Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING